Communiqués MediciNova, Inc.

Actions

MNOV

US58468P2065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
1,650 ^USD	-5,98%		-14,06%	+25,95%

28/09	MediciNova, Inc. modifie son contrat de bail et en repousse la date d’expiration au 30 avril 2030 avec Newport Gateway Office LLC	CI
28/09	Medicinova, Inc. annonce les résultats principaux de l’essai clinique MN-001-NATG-202 consacré au MN-001 (tipélukast)	CI

Communiqués

06/10	MediciNova to Participate in the Maxim Growth Summit	GL
29/09	MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)	AQ
28/09	MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)	GL
24/09	MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)	GL
08/09	MediciNova to Participate in Two Investor Conferences in September	GL
15/08	Maxim Group – 2Q26 Review & Outlook: Multiple Near-Term Events with Readouts in ALS and Metabolic Disease – August 14, 2026	PU
15/08	MediciNova : H.C. Wainwright & Co. – Advancing Dual-Asset Pipeline with Two Key Readouts on the Horizon; 2Q26 Results – August 14, 2026	PU
13/08	MediciNova: Q2 Earnings Snapshot	AQ
15/07	MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients	GL
15/07	MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients	AQ
30/06	MediciNova CEO Provides Shareholder Update	GL
08/06	MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment	GL
27/05	MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)	GL
15/05	MediciNova: Q1 Earnings Snapshot	AQ
28/04	New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation	GL
16/03	MediciNova to Participate at the 38th Annual ROTH Conference	GL
20/02	MediciNova: Q4 Earnings Snapshot	AQ
30/01	MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients	GL
06/01	2026 New Year’s Greetings from the CEO	GL
06/01	2026 New Year’s Greetings from the CEO	AQ
18/12	MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy	GL
08/12	MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND	GL
02/12	Message from the CEO to MediciNova Shareholders	GL
18/11	MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor	GL
12/11	MediciNova: Q3 Earnings Snapshot	AQ